PDS Biotech to Present VERSATILE-002 Data at ESMO 2024

PDS Biotechnology Corporation, a prominent late-stage immunotherapy company, is set to share new findings from its VERSATILE-002 trial involving Versamune® HPV and KEYTRUDA® (pembrolizumab). This trial focuses on treating HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, on September 14, 2024.

The key details of the presentation are as follows:
- Poster number: 879P
- Poster title: VERSATILE-002: Survival with First-Line Treatment with PDS0101 Therapeutic Vaccine and Pembrolizumab in HPV16-positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Presenting author: Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at the University of North Carolina, and Principal Investigator of the VERSATILE-002 clinical trial

PDS Biotechnology specializes in innovative immunotherapy, aiming to revolutionize the immune system's approach to targeting and destroying cancer cells and developing vaccines for infectious diseases. The company is preparing to start a pivotal clinical trial in 2024 to further its leading program in advanced HPV16-positive head and neck squamous cell cancers. Versamune® HPV, their leading investigational targeted immunotherapy, is being tested in combination with immune checkpoint inhibitors. Additionally, it is being evaluated in a triple combination therapy including PDS01ADC, an IL-12 fused antibody drug conjugate, and a standard immune checkpoint inhibitor.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!